Even if agonists for some of these genes exist (e.g., Afamelanotide, a α-melanocyte-stimulating hormone (MSH) analogue that binds MC1R) to treat some skin diseases51, because of the importance of sun exposure in keratinocyte carcinoma52, the modification of the melanin biosynthesis by those drugs as a treatment for BCC is questionable. Here, MC1R is linked to skin basal cell carcinoma.